The company is facing increasing competition for Ozempic and Wegovy, particularly from Eli Lilly. Lilly makes diabetes treatment Mounjaro and weight-loss drug Zepbound. They work similarly to Novo's ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Danish drugmaker Novo Nordisk (NVO) is in the red again after announcing CEO Lars Fruergaard Jørgensen is stepping down ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

The boss of the drugs giant behind Ozempic has quit after falling behind in the global race to develop weight-loss medication ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was ...

Jorgensen became CEO in January 2017 and the company’s market capitalization has more than tripled during his tenure. Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, but ...

Novo Nordisk said Jørgensen will remain in his role temporarily to ensure a “smooth transition” while a search for his ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will resign due to the company's declining market position in obesity drugs. Despite previous successes with Wegovy, shares have dropped amid intense ...